Ionis posts $105M TRYNGOLZA 2025 U.S. sales

Ionis Pharmaceuticals, Inc. reported preliminary 2025 U.S. net product sales of $105 million for its drug TRYNGOLZA.

Accepted by SEC EDGAR 01/12/2026 - 07:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals, Inc. reported preliminary 2025 U.S. net product sales of $105 million for its drug TRYNGOLZA. These figures are unaudited, may be adjusted, and are being shared ahead of the company’s full financial results, which are planned for February 2026. The sales number gives an early view of TRYNGOLZA’s commercial performance in the U.S. market but does not represent the company’s complete 2025 financial picture.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What sales figure did Ionis Pharmaceuticals (IONS) report for TRYNGOLZA in 2025?

Ionis Pharmaceuticals reported preliminary 2025 U.S. net product sales for TRYNGOLZA of $105 million.

Are Ionis Pharmaceuticals’ reported TRYNGOLZA 2025 sales final?

No. The reported TRYNGOLZA 2025 U.S. net product sales of $105 million are described as preliminary, unaudited, and subject to adjustment.

When will Ionis Pharmaceuticals (IONS) release full 2025 financial results?

Ionis Pharmaceuticals stated it plans to announce its complete financial results in February 2026.

What was the purpose of Ionis Pharmaceuticals’ January 12, 2026 announcement?

The company issued a press release on January 12, 2026 to announce preliminary 2025 U.S. net product sales for TRYNGOLZA of $105 million.

Is the TRYNGOLZA sales information considered filed under the Exchange Act?

Ionis stated that the information in Item 2.02 and the related exhibit is furnished, not filed, and is not subject to Section 18 liabilities or automatic incorporation by reference.

What exhibit accompanied Ionis Pharmaceuticals’ TRYNGOLZA sales disclosure?

The company attached a press release dated January 12, 2026 as Exhibit 99.1 and a Cover Page Interactive Data File as Exhibit 104.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000087401500008740152026-01-122026-01-12

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  January 12, 2026

IONIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-19125		33-0336973
(Commission File No.)		(IRS Employer Identification No.)

2855 Gazelle Court

Carlsbad, CA 92010

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (760) 931-9200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, $.001 Par Value		“IONS”		The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company                ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing TRYNGOLZA^® 2025 preliminary U.S. net product sales of $105 million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2026.

The information in this Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated January 12, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Ionis Pharmaceuticals, Inc.
Dated: January 12, 2026	By:	/s/ Patrick R. O’Neil
		Patrick R. O’Neil
		Executive Vice President, Chief Legal Officer and General Counsel